Bellerophon Therapeutics, Inc. (BLPH)
USD 0.01
(-36.84%)
USD 0.01
(-36.84%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.77 Million | -22.82 Million | -19.88 Million | -12.93 Million | -15.49 Million | -15.74 Million |
| Net Income | -19.83 Million | -17.75 Million | -24.72 Million | -13.26 Million | 2.81 Million | -54.81 Million |
| Depreciation & Amortization | 65 Thousand | 102 Thousand | 147 Thousand | 348 Thousand | 362 Thousand | 373 Thousand |
| Deferred income taxes | - | - | 327 Thousand | - | -2.81 Million | -6000.00 |
| Stock-based compensation | 786 Thousand | 1.12 Million | 1.63 Million | 2.15 Million | 2.95 Million | 2.84 Million |
| Change in working capital | 1.21 Million | -5.69 Million | 2.43 Million | -161 Thousand | 3.25 Million | 5.35 Million |
| Other non-cash items | -1000.00 | -600 Thousand | 300 Thousand | -2 Million | -22.06 Million | 30.51 Million |
| Investing Cash Flow | - | - | - | - | 3 Million | 2.57 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | -5.98 Million |
| Sales/Maturities of investments | - | - | - | - | 3 Million | 8.55 Million |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -40 Thousand | - | 57.56 Million | 6.16 Million | 166 Thousand | 27.78 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -28 Thousand | - |
| Common Stock Issuance | - | - | 54.69 Million | 6.23 Million | 166 Thousand | 25.25 Million |
| Other Financing Activities | -40 Thousand | - | 2.87 Million | -69 Thousand | 194 Thousand | 2.53 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 825 Thousand | -5.49 Million | 2.45 Million | -406 Thousand | 488 Thousand | 791 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 386 Thousand | -200 Thousand | -15 Thousand | 245 Thousand | 2.76 Million | 4.56 Million |
| Cash at beginning of period | 25.13 Million | 47.96 Million | 10.27 Million | 17.04 Million | 29.37 Million | 14.2 Million |
| Cash at end of period | 7.32 Million | 25.13 Million | 47.96 Million | 10.27 Million | 17.04 Million | 28.82 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -17.81 Million | -22.82 Million | 37.68 Million | -6.76 Million | -12.32 Million | 14.62 Million |
| Free Cash Flow | -17.77 Million | -22.82 Million | -19.88 Million | -12.93 Million | -15.49 Million | -15.74 Million |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.92 Million | -5.13 Million | 2.82 Million | -5.01 Million | -19.83 Million | -5.06 Million |
| Depreciation & Amortization | - | 1000.00 | 1000.00 | 4000.00 | 65 Thousand | 21 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 21 Thousand | 133 Thousand | 264 Thousand | 162 Thousand | 786 Thousand | 217 Thousand |
| Change in working capital | -4.29 Million | 83 Thousand | 179 Thousand | 499 Thousand | 1.21 Million | -179 Thousand |
| Other non-cash items | -140 Thousand | -131 Thousand | 127 Thousand | -1000.00 | -1000.00 | - |
| Investing Cash Flow | 140 Thousand | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | 140 Thousand | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | 26 Thousand | 4.98 Million | -0.04 | -40 Thousand | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 28 Thousand | 1.43 Million | - | - | - |
| Other Financing Activities | - | 26 Thousand | 3.54 Million | -0.04 | -40 Thousand | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -4.36 Million | 266 Thousand | 139 Thousand | 395 Thousand | 825 Thousand | -98 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 74 Thousand | -183 Thousand | -139 Thousand | 104 Thousand | 386 Thousand | - |
| Cash at beginning of period | 10.68 Million | 15.57 Million | 7.32 Million | 11.72 Million | 25.13 Million | 16.73 Million |
| Cash at end of period | 4.49 Million | 10.68 Million | 15.57 Million | 7.32 Million | 7.32 Million | 11.72 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -6.19 Million | -4.89 Million | 8.24 Million | -4.39 Million | -17.81 Million | -5.01 Million |
| Free Cash Flow | -6.33 Million | -4.92 Million | 3.26 Million | -4.35 Million | -17.77 Million | -5.01 Million |
5134
RIGS
RTOXF
601929
CEOS
UNIP3